Table 1:
Patient characteristics (n = 2030)
| Missing information | ||
|---|---|---|
| Age, median (IQR) | 56 (45;67) | 3 (<1%) |
| Males | 1042 (51%) | 1 (<1%) |
| Myasthenia gravis | 629 (35%) | 243 (12%) |
| T size, median (IQR) | 6 (4;7) | 527 (26%) |
| Masaoka stage | ||
| 1 | 672 (34%) | 34 (2%) |
| 2 | 699 (35%) | |
| 3 | 410 (21%) | |
| 4 | 215 (11%) | |
| Diagnosis | ||
| Thymoma WHO A-AB-B1 | 1018 (50%) | 0 (0%) |
| Thymoma WHO B2-B3 | 780 (38%) | |
| Thymic carcinoma | 191 (9%) | |
| NETT | 41 (2%) | |
| Complete resections (R0) | 1709 (88%) | 80 (4%) |
| Intervention period | ||
| 1990–1995 | 176 (9%) | 0 (0%) |
| 1996–2001 | 395 (19%) | |
| 2002–2007 | 858 (42%) | |
| 2008–2011 | 601 (30%) | |
| Mean number of patients treated yearly by centre | ||
| ≤4 [19 (54%) centres] | 532 (26%) | 0 (0%) |
| 5–9 [11 (31%) centres] | 680 (33%) | |
| ≥10 [ 5 (14%) centres] | 818 (40%) | |
| Induction therapy | 239 (13%) | 154 (8%) |
| CT alone | 170 (9%) | |
| RT alone | 12 (1%) | |
| CT and RT | 57 (3%) | |
| Adjuvant therapy | 853 (44%) | 76 (4%) |
| CT alone | 44 (2%) | |
| RT alone | 566 (29%) | |
| CT and RT | 243 (12%) | |
Data are n (%) unless otherwise indicated. Percentages are calculated on the basis of available data for each characteristics.
CT: chemotherapy; NETT: neuroendocrine thymic tumour; RT: radiotherapy.